Using small molecules to enhance cancer immunotherapy through a new cell death mechanism
Official title: Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy
Funded at Research Inst of Fox Chase Can Ctr · NIH-11035222 · Data updated 2026-11-12
This study is exploring a new way to boost cancer treatment by using special molecules to help your immune system recognize and fight tumors that usually resist current therapies, aiming to improve outcomes for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $758,985 |
| NIH project number | 5R01CA269975-03 |
| Project ID | NIH-11035222 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with 'cold' tumors that have shown resistance to current immunotherapy treatments.
✕Less likely to help
Patients with tumors that are already responsive to existing immunotherapies may not benefit from this research.
What this research studies
This research investigates a novel approach to improve cancer immunotherapy by activating a specific type of cell death called necroptosis, which can enhance the immune response against tumors. The researchers aim to use small molecules that trigger necroptosis in cancer cells, making them more visible to the immune system. By focusing on tumors that are typically resistant to existing therapies, this approach seeks to create a more immunogenic tumor microenvironment, potentially leading to better treatment outcomes for patients. The study builds on previous findings related to viral infections and their ability to stimulate immune responses.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments for patients whose tumors currently do not respond to standard immunotherapies.
How similar studies have gone: While the approach of using small molecules to activate necroptosis is innovative, similar strategies targeting immune responses in cancer have shown promise in other studies.
Where this research is happening
-
Research Inst of Fox Chase Can Ctr
Philadelphia, United States Active
Researchers
- Principal investigator: Balachandran, Siddharth — Research Inst of Fox Chase Can Ctr
- Study coordinator: Balachandran, Siddharth
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.